Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
In development
Reference number: GID-TA11400
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2025.